Last reviewed · How we verify
NCT07247942
Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.
Phase 1 trial testing zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour in Healthy Subjects (HS) in 8 participants. Completed in 30 January 2019.
20 January 2018
Quick facts
| Lead sponsor | Wockhardt |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 8 |
| Start date | 13 December 2017 |
| Primary completion | 20 January 2018 |
| Estimated completion | 30 January 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour — full drug profile →
Conditions studied
- Healthy Subjects (HS) — all drugs for Healthy Subjects (HS) →
Sponsor
Wockhardt — full company profile →
Who can join
Adults 18 to 55, male only, with Healthy Subjects (HS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1, Open-label Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion in Healthy Male Subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07247942
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Subjects (HS)
Currently open trials in the same condition.
- NCT07528742 — Vagus Nerve Stimulation for Reaction Time · NA · recruiting
- NCT07364149 — Acute Effects of Structured Exercise and Static Stretching on Vascular Function, Neuromuscular Performance, and Metaboli · NA · recruiting
- NCT07241923 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 Inj · Phase 1 · recruiting
- NCT06774833 — Self-initiated Perturbation-based Training in Older Adults · NA · recruiting
- NCT06884488 — Aftereffects of PES Preconditioned with RTMS on the Human Pharyngeal Motor Cortex · NA · recruiting
Other Wockhardt trials
Trials by the same sponsor.
- NCT06806995 — A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Met · Phase 1 · completed
- NCT04979806 — Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) · Phase 3 · completed
- NCT03981887 — Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin · Phase 1 · completed
- NCT03622008 — To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) · Phase 1 · completed
- NCT03405064 — Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Struct · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07247942 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wockhardt
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07247942.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing